Delving into the Latest Updates on CBCC Global Research LLP with Synapse

Overview

A randomized, open label, multi-center, two-treatment, two-period, two-sequence, fully replicate, cross-over, multiple dose, steady-state, bioequivalence study of Olaparib Tablets 150 mg (2x150 mg tablets) of Alembic Pharmaceuticals Limited, India with Lynparza® 150mg Filmtabletten Olaparib (2x150 mg tablets) of AstraZeneca AB, SE-151 85 Södertälje, Schweden, in adult patients with carcinoma of the ovary, breast, prostate or adenocarcinoma of the pancreas under fasting condition. - NIL

Start Date14 Nov 2024

Sponsor / Collaborator

Alembic Pharmaceuticals Ltd.

[+1]

CTRI/2024/10/074896 / Not yet recruitingNot Applicable

A randomized, open label, multi-center, two-treatment, two-period, two-sequence, fully replicate, cross-over, multiple dose, steady-state, bioequivalence study of Olaparib Tablets 150 mg (2x150 mg tablets) of Alembic Pharmaceuticals Limited, India with Lynparza® 150mg Filmtabletten Olaparib (2x150 mg tablets) of AstraZeneca AB, SE-151 85 Södertälje, Schweden, in patients with ovarian cancer, breast cancer, prostate cancer or adenocarcinoma of the pancreas under fed condition. - NIL

Start Date01 Nov 2024

Sponsor / Collaborator

Alembic Pharmaceuticals Ltd.

[+1]

CTRI/2024/09/073306 / RecruitingNot Applicable

A randomized, open-label, balanced, multi-center, two-treatment, four-period, two-sequence, single dose, crossover, fully replicate, bioequivalence (BE) study of Azacitidine tablets 300 mg of Qilu Pharmaceutical Co., Ltd with ONUREG (Azacitidine) tablets 300 mg of Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, 86 Morris Avenue, Summit, NJ 07901 in patients with Acute Myeloid Leukemia. - NIL

Start Date07 Sep 2024

Sponsor / Collaborator